Mascarenhas, John <br/><br/>
A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).  [electronic resource] 

 -  Leukemia research  02 2017 
 - 13-19 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1873-5835 
<br/><br/><label>Standard No.: </label>10.1016/j.leukres.2016.11.015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Female<br/>Histone Deacetylase Inhibitors--administration & dosage<br/>Humans<br/>Hydroxamic Acids--administration & dosage<br/>Indoles--administration & dosage<br/>Janus Kinase 2--genetics<br/>Male<br/>Middle Aged<br/>Organ Size<br/>Panobinostat<br/>Polycythemia Vera--drug therapy<br/>Primary Myelofibrosis--drug therapy<br/>Spleen--pathology<br/>Thrombocythemia, Essential--drug therapy<br/>Treatment Outcome